Cardiovascular in Medical Technology
Navigation Links
Cardiovascular in Medical Technology
... and their effects on reducing the risks of cardiovascular disease in older adults.
cardiovascular disease caused by atherosclerosis, or the ... aging and that contribute to increased risk for cardiovascular disease. GH has been found to decrease total body ...
... for Industry: Diabetes Mellitus -- Evaluating cardiovascular Risk in New Antidiabetic Therapies to Treat Type ... 26, the FDA asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA ... includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other ...
... addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal ... be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome." ... and is in pre-clinical development for cardiovascular and liver disease indications. Cardax ...
... in discussions about conducting an additional cardiovascular study for alogliptin. As previously ... for Industry: Diabetes Mellitus -- Evaluating cardiovascular Risk in New Antidiabetic Therapies to Treat Type ... The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA ...
... program. Corventis is a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions. (Logo: ... Corventis, Inc. is a pioneer in wireless cardiovascular solutions. The company's technology enables ...
... the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an ... of atherosclerosis. The Company's Phase 3 cardiovascular outcome study will assess the effect of VIA-2291 in preventing cardiovascular events such as heart attack, stroke ...
... consider whether their patients with underlying cardiovascular disease could be adversely affected by such ... vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive ... of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g] ...
... cardiovascular Safety and Potential Benefits of Exenatide to be ... ) today announced results from a meta-analysis of cardiovascular (CV) events that showed no increased risk of CV ... data that show favorable effects of exenatide on cardiovascular risk factors," said Byron Hoogwerf, M.D., ...
... (ASE) welcomes the world's leading researchers in cardiovascular medicine to present their most-recent findings at ... unveiled at ASE's Scientific Sessions. By using cardiovascular ultrasound and other objective tests, physicians ... the use of ultrasound to image the heart and cardiovascular system. The organization was founded in 1975 and ...
... SAN FRANCISCO, June 8 /PRNewswire/ -- MAQUET cardiovascular LLC announced today that data presented at the ... and patient outcomes." About MAQUET cardiovascular MAQUET cardiovascular LLC is a division of MAQUET Medical Systems, part ...
... their treatment options. The Society for cardiovascular Angiography and Interventions (SCAI) encourages ... 2 diabetes mellitus and CAD are at high risk for cardiovascular events, including heart attack. According to the ... should not be generalized across broad groups of cardiovascular patients. As always, SCAI emphasizes each ...
... in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk ... in multiple secondary endpoints associated with cardiovascular risk, including: Blood ... resistance Inflammatory Markers of cardiovascular Risk: high-sensitivity CRP and fibrinogen ...
... annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia ... was initiated in 2001, and designed to compare cardiovascular outcomes of patients on Avandia added to ...
... and CICT collaborate by reconstructing cardiovascular clinical experiences presented virtually at the ... Company, and its partner Complex Interventional cardiovascular Therapy (CICT) announced a collaboration using ... for complex clinical skills development in cardiovascular medicine. The partnership underscores the ...
... predictors of the two outcome measures: 60-day cardiovascular (CV) death or re-admission for heart failure and ... for heart failure and no patients died of cardiovascular causes, as compared to 17% in the placebo group ... no patients in the relaxin-30 group had died of cardiovascular causes, as compared to 14% of those in the ...
... surgeons at the Clinic for Thoracic and cardiovascular Surgery, Heart and Diabetes Center NRW, ... and Cardiac Transplantation, Gerald McGinnis cardiovascular Institute, Allegheny General Hospital, treated ... and Director of the Clinic for Thoracic and cardiovascular Surgery, Heart and Diabetes Center NRW, ...
... channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing ... of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio ... has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead ...
... disease, as well as an important risk factor of cardiovascular disease (CVD).(1) The secondary objective of the ROADMAP trial includes incidence of cardiovascular and renal morbidity and mortality. A qualitative ... olmesartan medoxomil has a positive effect on cardiovascular and renal morbidity and mortality. The ...
... the annual scientific meeting of the Society for cardiovascular Angiography and Interventions (SCAI). The ... decrease the effectiveness of clopidogrel and put cardiovascular patients at a much higher risk - a huge concern ... of the four most popular PPIs." The adverse cardiovascular events that were measured in the study include ...
... Recurrent Acute coronary events with Near-term cardiovascular Inflammation Suppression), a clinical trial ... from our first two clinical studies in stable cardiovascular patients, the FRANCIS study has validated the ... 1000 patient exposures to date in three cardiovascular studies, varespladib has been generally well ...
... from aspirin because of their higher risk of cardiovascular disease, but the harms are also greater because ... of Public Health and Information. cardiovascular disease is the leading cause of death in the ... In 2003, 1 in every 3 adults had some type of cardiovascular disease. In adults over the age of 40, the risk ...
... said Richard Becker, MD, director of the Duke cardiovascular Thrombosis Center and lead author of the study. ... group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough Research ... addition to standard-of-care therapies had fewer cardiovascular events such as heart attack, need for urgent ...
... developing serious medical conditions, including cardiovascular disease and diabetes, particularly when their ... ideal body weight and get routine screenings for cardiovascular risk factors -- such as blood pressure and ... psoriasis patients about the increased risk of cardiovascular disease so the prevention efforts can be ...
... disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and ... significant 27% relative reduction in the risk of cardiovascular events, compared with 11% in FIELD patients ...
... 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes ... GlaxoSmithKline has advanced both darapladib for cardiovascular disease and Syncria for type 2 diabetes to Phase ... inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary ...
... (dronedarone) significantly reduced the risk of cardiovascular hospitalization or death by 24 percent in ... therapy, significantly reduced the risk of first cardiovascular hospitalization or death by 24 percent (31.9% vs. ... worsens the prognosis of patients with cardiovascular risk factors(4) and that doubles the risk of ...
... for Industry: Diabetes Mellitus -- Evaluating cardiovascular Risk in New Antidiabetic Therapies to Treat Type ... 26, the FDA asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA ... includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other ...
... addresses metabolic syndrome, including liver and cardiovascular disease as well as diabetes. Preclinical animal ... be a new paradigm for the treatment of liver and cardiovascular disease as well as metabolic syndrome." ... and is in pre-clinical development for cardiovascular and liver disease indications. Cardax ...
St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures
... that allows patients to rebuild their own cardiovascular tissue. (Logo: ... CorMatrix(R) ECM Technology(TM) CorMatrix cardiovascular holds an exclusive license from Purdue ... market naturally occurring ECM(TM) products for cardiovascular applications. The company currently has U.S. ...Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
... include Dr. Doris Taylor's, Director, Center for cardiovascular Repair, University of Minnesota , recollection ... functional outcome." Dr. Nabil Dib, Director, cardiovascular Research, Mercy Gilbert & Chandler Medical ... monitor, diagnose and treat heart failure and cardiovascular diseases. Its goals are to improve a patient's ...... in discussions about conducting an additional cardiovascular study for alogliptin. As previously ... for Industry: Diabetes Mellitus -- Evaluating cardiovascular Risk in New Antidiabetic Therapies to Treat Type ... The FDA has asked Takeda to conduct an additional cardiovascular safety trial that satisfies the December 2008 FDA ...
... program. Corventis is a developer of wireless cardiovascular solutions designed to enable early detection, prevention and treatment of cardiovascular conditions. (Logo: ... Corventis, Inc. is a pioneer in wireless cardiovascular solutions. The company's technology enables ...
... the development of compounds for the treatment of cardiovascular and metabolic disease, announced today that an ... of atherosclerosis. The Company's Phase 3 cardiovascular outcome study will assess the effect of VIA-2291 in preventing cardiovascular events such as heart attack, stroke ...
... consider whether their patients with underlying cardiovascular disease could be adversely affected by such ... vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive ... of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. [uthr-g] ...
... cardiovascular Safety and Potential Benefits of Exenatide to be ... ) today announced results from a meta-analysis of cardiovascular (CV) events that showed no increased risk of CV ... data that show favorable effects of exenatide on cardiovascular risk factors," said Byron Hoogwerf, M.D., ...
... (ASE) welcomes the world's leading researchers in cardiovascular medicine to present their most-recent findings at ... unveiled at ASE's Scientific Sessions. By using cardiovascular ultrasound and other objective tests, physicians ... the use of ultrasound to image the heart and cardiovascular system. The organization was founded in 1975 and ...
... SAN FRANCISCO, June 8 /PRNewswire/ -- MAQUET cardiovascular LLC announced today that data presented at the ... and patient outcomes." About MAQUET cardiovascular MAQUET cardiovascular LLC is a division of MAQUET Medical Systems, part ...
Research: Popular Diabetes Medications Associated with Increase in Bone Fractures
... drug class, which has also been associated with cardiovascular issues. Troglitazone, the third of three major ... and Proton Pump Inhibitors at Greater Risk for cardiovascular Events New research from the Clopidogrel ... (CMOS) has revealed an increased risk for major cardiovascular events in patients with diabetes who take ...... their treatment options. The Society for cardiovascular Angiography and Interventions (SCAI) encourages ... 2 diabetes mellitus and CAD are at high risk for cardiovascular events, including heart attack. According to the ... should not be generalized across broad groups of cardiovascular patients. As always, SCAI emphasizes each ...
... in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk ... in multiple secondary endpoints associated with cardiovascular risk, including: Blood ... resistance Inflammatory Markers of cardiovascular Risk: high-sensitivity CRP and fibrinogen ...
... annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia ... was initiated in 2001, and designed to compare cardiovascular outcomes of patients on Avandia added to ...
... and CICT collaborate by reconstructing cardiovascular clinical experiences presented virtually at the ... Company, and its partner Complex Interventional cardiovascular Therapy (CICT) announced a collaboration using ... for complex clinical skills development in cardiovascular medicine. The partnership underscores the ...
... predictors of the two outcome measures: 60-day cardiovascular (CV) death or re-admission for heart failure and ... for heart failure and no patients died of cardiovascular causes, as compared to 17% in the placebo group ... no patients in the relaxin-30 group had died of cardiovascular causes, as compared to 14% of those in the ...
Cardiovascular Fitness Not Affected by Cancer Treatment
... Survivors Start Exercise Routine Based on Current cardiovascular Fitness Level WASHINGTON, May 28 /PRNewswire-USNewswire/ -- The cardiovascular fitness level of cancer survivors is not affected ... or not treatment has had an impact on their cardiovascular health." For the study, the researchers ...FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
... consider whether their patients with underlying cardiovascular disease could be adversely affected by such ... vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive ... of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer. ...... surgeons at the Clinic for Thoracic and cardiovascular Surgery, Heart and Diabetes Center NRW, ... and Cardiac Transplantation, Gerald McGinnis cardiovascular Institute, Allegheny General Hospital, treated ... and Director of the Clinic for Thoracic and cardiovascular Surgery, Heart and Diabetes Center NRW, ...
Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient
... is not enough to reveal an individual's risk for cardiovascular disease Saturday at the American Association of ... weight, doctors can better predict the multiple cardiovascular risks likely to prey upon a patient. ... them at risk for developing type 2 diabetes and cardiovascular complications. To download these recommendations ...... channel agonist with potential utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing ... of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio ... has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead ...
... disease, as well as an important risk factor of cardiovascular disease (CVD).(1) The secondary objective of the ROADMAP trial includes incidence of cardiovascular and renal morbidity and mortality. A qualitative ... olmesartan medoxomil has a positive effect on cardiovascular and renal morbidity and mortality. The ...
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
... illnesses such as hypertension, diabetes, cardiovascular disease and stroke. Patients are in urgent need ... life-threatening conditions including diabetes, cardiovascular disease, hypertension and stroke. Experts agree ... weight loss, glycemic control, and improvement in cardiovascular risk factors. Qnexa is well tolerated, with no ...... the annual scientific meeting of the Society for cardiovascular Angiography and Interventions (SCAI). The ... decrease the effectiveness of clopidogrel and put cardiovascular patients at a much higher risk - a huge concern ... of the four most popular PPIs." The adverse cardiovascular events that were measured in the study include ...
... Recurrent Acute coronary events with Near-term cardiovascular Inflammation Suppression), a clinical trial ... from our first two clinical studies in stable cardiovascular patients, the FRANCIS study has validated the ... 1000 patient exposures to date in three cardiovascular studies, varespladib has been generally well ...
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
... CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those ... (PCI), the incidence of the combined endpoint of cardiovascular death, heart attack or stroke was 8.5 percent ... gene are associated with an increased risk of cardiovascular outcomes in patients treated with clopidogrel," ...Isis and Collaborators Present New Research at the ATVB Annual Conference
... data on numerous advanced programs from Isis' cardiovascular franchise. The data were presented during the ... the potential to provide unique treatments for cardiovascular disease. Isis and collaborators also presented ... against 11 beta-HSD1 and apoF, potential new cardiovascular targets. The research presented at this year's ...CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
... of LDL-C and hsCRP had a greater reduction in cardiovascular events." Rosuvastatin 20mg was well ... the impact of rosuvastatin 20mg on reducing major cardiovascular (CV) events (combined risk of myocardial ... with an increased risk of atherosclerotic cardiovascular events. JUPITER is a part of AstraZeneca's ...CRESTOR(R) Reduced Risk of Blood Clots in the Veins
... US. "This result is in addition to the effect on cardiovascular events already demonstrated by CRESTOR in the ... the risk of heart attack, stroke and other major cardiovascular events in patients with low to normal LDL-C but at increased cardiovascular risk as identified by elevated high-sensitivity ...... from aspirin because of their higher risk of cardiovascular disease, but the harms are also greater because ... of Public Health and Information. cardiovascular disease is the leading cause of death in the ... In 2003, 1 in every 3 adults had some type of cardiovascular disease. In adults over the age of 40, the risk ...
... said Richard Becker, MD, director of the Duke cardiovascular Thrombosis Center and lead author of the study. ... group vice president of global clinical research, cardiovascular and metabolic disease, Schering-Plough Research ... addition to standard-of-care therapies had fewer cardiovascular events such as heart attack, need for urgent ...
... developing serious medical conditions, including cardiovascular disease and diabetes, particularly when their ... ideal body weight and get routine screenings for cardiovascular risk factors -- such as blood pressure and ... psoriasis patients about the increased risk of cardiovascular disease so the prevention efforts can be ...
... disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and ... significant 27% relative reduction in the risk of cardiovascular events, compared with 11% in FIELD patients ...
... 2009 - - Phase 3 trials of darapladib for cardiovascular disease and Syncria(R) for type 2 diabetes ... GlaxoSmithKline has advanced both darapladib for cardiovascular disease and Syncria for type 2 diabetes to Phase ... inhibitor darapladib to reduce the risk of cardiovascular events in men and women with chronic coronary ...
Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
... - hold particular relevance to Hoosiers because cardiovascular disease and stroke are the leading causes of ... many factors that increase the risk of developing cardiovascular disease, including higher-than-national rates for ... allowed us to better control the risk factors for cardiovascular events and has helped significantly cut deaths ...CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial
... LAS VEGAS, Feb. 24 /PRNewswire-FirstCall/ -- cardiovascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) ... company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow ... to their spine. For more information about cardiovascular BioTherapeutics, Inc. please visit www.cvbt.com ....Savient Provides Update on Pegloticase BLA
... to the BLA Clearer Data on cardiovascular Profile. The results of the Company's independent post hoc both blinded and unblinded cardiovascular adjudication provided additional data, which clarified the previous understanding of the cardiovascular profiles of pegloticase. Further details of these ...... (dronedarone) significantly reduced the risk of cardiovascular hospitalization or death by 24 percent in ... therapy, significantly reduced the risk of first cardiovascular hospitalization or death by 24 percent (31.9% vs. ... worsens the prognosis of patients with cardiovascular risk factors(4) and that doubles the risk of ...
Other ContentsliftliftliftliftliftliftforeheadforeheadforeheadforeheadhistoryhistoryhistoryhistoryhistoryhistoryhistoryhistoryhistorybasedbasedbasedbasedbasedbasedbasedbasedbasedbasedgendergendergendergendergendergenderresearchresearchresearchresearchresearchresearchresearchresearchresearchresearchhealthhealthhealthhealthhealthhealthhealthhealthhealthruleruleruleruleruleruleruleruleOther TagsunwantedcreamShortenaxialOther Tagsreferred 2referred 3referred 4referred 5referred 6referred 7referred 8referred 9referred 10depression 2depression 3risky 2smoke 2smoke 3tobacco 2tobacco 3any 2any 3any 4any 5any 6any 7any 8any 9any 10
(Date:11/24/2009)... ROUGE Antarctica has long held secrets of the ea...recently, there has been very little information o...iles of ice for millions of years. Now, a team of ... have been funded to the tune of $10 million dolla...get to the bottom of things literally. These scie...
(Date:11/23/2009)...ton, D.C. The community-associated strain of the ...resistant to most common antibioticsposes a far gr...aking its way into hospitals, according to a study...eases . , The new threat is easily picked up in... and has increased the overall burden of MRSA with...
(Date:11/23/2009)...ton, CT Current research suggests that a common o...The related report by Nichols et al, "Unique Lipid...ass of TLR2 Ligands Capable of Enhancing Autoimmun...merican Journal of Pathology . , Multiple sclero...s the brain and spinal cord, affects nearly 1 in 7...
Breaking Biology News(10 mins):LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2URAC Seeks Public Input on New Uniform External Review Standards for Health Plan and Health Utilization Management Organizations 51887 1URAC Seeks Public Input on New Uniform External Review Standards for Health Plan and Health Utilization Management Organizations 51887 2URAC Seeks Public Input on New Uniform External Review Standards for Health Plan and Health Utilization Management Organizations 51887 3Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel 28R 29 51884 1Biostar Pharmaceuticals Inc Receives Government Approvals for Three New Products 51881 1Biostar Pharmaceuticals Inc Receives Government Approvals for Three New Products 51881 2Biostar Pharmaceuticals Inc Receives Government Approvals for Three New Products 51881 3Biostar Pharmaceuticals Inc Receives Government Approvals for Three New Products 51881 4(Date:11/25/2009)...NTOandCALGARY,Nov.25/PRNewswire/-SentinelleMedical...g(MRI)coilsandsoftwareandCalgaryScientificInc.,ale...troducedawebversionofAegis(TM)Breast4DAdvancedVisu...thefirsttrulyzero-footprintWebclientbasedmedicalim...b(TM)platformallowsforzero-footprintaccess-requiri...
(Date:11/25/2009)...RANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQualityM... Spare the Air Alert forThursday,Nove...gsoranyothersolidfuel,bothindoorsandoutdoors. ,...alitytomorrow,"saidJackBroadbent,executiveofficero...ectthehealthoftheirneighborsandfellowcommunitymemb...
(Date:11/25/2009)...s increase blood pressure? This simple question h...rs. New Stress-related gene Modulates High Blood ...d pressure? This simple question has been the foc...search has for the first time established a link b...sure response to stress in mice as well as humans....
(Date:11/25/2009)...ten plagued by neurological symptoms, study finds ... -- Neurological side effects are among the potent...cular cancer who were treated with cisplatin-based...dy included 1,409 Norwegian men treated for unilat...ook part in a follow-up survey conducted from 1998...
(Date:11/25/2009)... Mass. -- A cancer vaccine carried into the body o... is the first to successfully eliminate tumors in ...l Science Translational Medicine . , The new ap...s at Harvard University, uses plastic disks impreg...nder the skin to reprogram the mammalian immune sy...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2[0] Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology[0] Winter Spare the Air Alert in Effect for Thursday, November 26, 2009[0] New stress-related gene modulates high blood pressure in mice and men[0] Long-Term Problems Linked to Testicular Cancer Chemo[1] Implant-based cancer vaccine is first to eliminate tumors in mice
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |